Table 1.
Characteristics | NAC-CCRTa | CCRT-ACb | p-value |
---|---|---|---|
N = 79 | N = 187 | ||
Age: Mean (SD) | 47.9 (12.6) | 51.9 (11.2) | 0.011 |
Min-Max | |||
Gender: Men | 56 (71%) | 129 (69%) | 0.880 |
Women | 23 (29%) | 58 (31%) | |
WHO classification: Type I | 3 (4%) | 4 (2%) | 0.640 |
Type II | 51 (65%) | 126 (67%) | |
Type III | 25 (32%) | 57 (31%) | |
T stage: T1 | 11 (14%) | 53 (28%) | < 0.001 |
T2 | 15 (19%) | 51 (27%) | |
T3 | 10 (13%) | 41 (22%) | |
T4 | 43 (54%) | 42 (23%) | |
N stage: N0 | 11 (14%) | 24 (13%) | < 0.001 |
N1 | 9 (11%) | 38 (20%) | |
N2 | 30 (38%) | 109 (58%) | |
N3 | 29 (37%) | 16 (9%) | |
AJCC staging: II-III | 11 (14%) | 132 (71%) | < 0.001 |
IVA-IVB | 68 (86%) | 55 (29%) |
aNAC-CCRT: neoadjuvant chemotherapy followed by concurrent chemo-radiotherapy
bCCRT-AC: concurrent chemo-radiotherapy followed by adjuvant chemotherapy